A combination therapy that adds a recently approved drug to the current standard of care for newly diagnosed acute myeloid ...

Johnson & Johnson announced new Phase 1b data showing antileukemic activity and a safety profile for bleximenib in ...

A combination of acalabrutinib and venetoclax showed better results with the addition of obinutuzumab, whereas mixed findings ...